Perspective · 10 Sep 2026
Conference abstractPublished 28 Sep 2015
Targeting the elusive Sézary cell
The University of Texas MD Anderson Cancer Center, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The SÃ?©zary cell is a puzzling malignant vs activated white blood cell first discovered by dermatologist Albert SÃ?©zary. He described the cell with a cerebriform nucleus in patients with erythroderma. Later it was found to be a T-cell by Lutz and others at the NIH and was suspiciously similar to HTLV-1 adult T-cell leukemia although no virus has yet been implicated. Recently, staging has been updated to include blood involvement for patients with SS and the mycosis fungoides form of cutaneous T cell lymphomas. The clinical features of SS are distinct from other forms of CTCL and include erythema >80%, keratoderma, ectropion, reactive adenopathy, and severe pruritus. The role of staphylococcus and drug induced disease suggests that some patients have persistent antigene stimulation as an initiating factor. Several other clinical Cutaneous T cell lymphomas (CTCL) have been described using clinical features, and histopathologic markers: The CD30 lymphoproliferative disorders, gamma delta lymphomas, subcutaneous panniculitic T cell lymphoma. The molecular basis for MF/SS has been the subject of intense basic research efforts. Genetic studies of the SS cell uncovered genetic instablility with multiple deletions and gains seen by karyotyping and by array CGH. Whole genome sequencing of SS and MF DNA has revealed somatic mutations that may help us to understand what drives the proliferation of the SS cell. Understanding the pathogenesis of the SS cell has translated into new targeted therapies for both SS and MF. These include fusion proteins (denileukin diftitoxin and CD3-diptheria toxin), monoclonal antibodies targeted to CD4, CCR4, CD52, KIRD3L, and CD30. In addition, small molecules such as histonedeacetylase inhibitors have shown sensitivity in SS. Another break through has been in the area of non-ablative allogeneic stem cell transplant that offers cure to a subset of patients. In summary, the future looks bright to finally silence the elusive SÃ?©zary cell in the not too distant future.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Madeleine Duvic”
